	US 12,465,628 B2
	Cannabinoid carrier compositions having enhance pharmacokinetic properties and methods of use thereof
Heather Florio, Hillsborough, NC (US)
Assigned to Desert Harvest, Inc., Ellsworth, ME (US)
Filed by Desert Harvest, Inc., Hillsborough, NC (US)
Filed on Mar. 9, 2023, as Appl. No. 18/181,014.
Application 18/181,014 is a continuation of application No. 16/772,055, abandoned, previously published as PCT/US2020/035708, filed on Jun. 2, 2020.
Claims priority of provisional application 62/971,496, filed on Feb. 7, 2020.
Prior Publication US 2023/0210935 A1, Jul. 6, 2023
Int. Cl. A61K 36/886 (2006.01); A61K 9/00 (2006.01); A61K 31/00 (2006.01); A61K 36/185 (2006.01); A61P 25/04 (2006.01)

CPC A61K 36/886 (2013.01) [A61K 9/0053 (2013.01); A61K 31/658 (2023.05); A61K 36/185 (2013.01); A61P 25/04 (2018.01); A61K 2236/53 (2013.01)]

13 Claims

1. A method for treating chronic pain associated with interstitial cystitis, rheumatoid arthritis, fibromyalgia, nerve damage, or osteoarthritis in a subject in need thereof comprising, administering a therapeutically effective amount of composition including a whole leaf aloe vera extract that is charcoal activated such that anthraquinones and insoluble fibers are removed, solubilizing a Cannabis extract in the whole leaf aloe vera extract, wherein said Cannabis extract comprises a cannabidiol (CBD) isolate, and wherein said CBD isolate exhibits enhanced bioavailability when administered to said subject and increased effectiveness for treating chronic pain against administering Cannabis extract without the whole leaf aloe vera extract, wherein the composition is not a nanoemulsion or liposomes, the CBD isolate is about 48 mg and administered orally.